Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
ERAS-801 in Gliosarcoma: NCT07089641 Clinical Landscape Report 2026
28 September 2026
NCT07089641 clinical landscape for Gliosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
tanCART-19/22 cells(Chinese PLA General Hospital) in High grade B-cell lymphoma: NCT07094477 Clinical Landscape Report 2026
28 September 2026
NCT07094477 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pazopanib Hydrochloride in Renal Cell Carcinoma: ACTRN12625000814471 Clinical Landscape Report 2026
28 September 2026
ACTRN12625000814471 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vevoctadekin in Refractory Indolent Non-Hodgkin Lymphoma: NCT07098364 Clinical Landscape Report 2026
28 September 2026
NCT07098364 clinical landscape for Refractory Indolent Non-Hodgkin Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Celecoxib in Triple Negative Breast Cancer: NCT07104266 Clinical Landscape Report 2026
28 September 2026
NCT07104266 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imdatifan in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT07097935 Clinical Landscape Report 2026
28 September 2026
NCT07097935 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Toripalimab in Triple Negative Breast Cancer: NCT07101614 Clinical Landscape Report 2026
28 September 2026
NCT07101614 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lomustine in Glioblastoma Multiforme: NCT07100730 Clinical Landscape Report 2026
28 September 2026
NCT07100730 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LY-4152199 in Follicular Lymphoma: NCT07101328 Clinical Landscape Report 2026
28 September 2026
NCT07101328 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Triple Negative Breast Cancer: NCT07103447 Clinical Landscape Report 2026
28 September 2026
NCT07103447 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCD-236 in Recurrent Triple-Negative Breast Carcinoma: NCT07108309 Clinical Landscape Report 2026
28 September 2026
NCT07108309 clinical landscape for Recurrent Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Cyclophosphamide in Triple Negative Breast Cancer: NCT07107217 Clinical Landscape Report 2026
28 September 2026
NCT07107217 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.